“Essential Medical announced the completion of enrollment in the U.S. pivotal investigational device exemption (IDE) trial of the Manta large bore vascular closure device.”
“As payers and other healthcare entities look to better manage costs, especially in the acute care setting, it is important to note that there are some clinical areas where the hospital’s margins are already modest and shrinking.”
“The U.S. Food and Drug Administration (FDA) announced clearance for NuMed’s Cheatham Platinum (CP) Stent System, which includes the Covered CP Stent and the Covered Mounted CP Stent.”
“Vasorum Ltd, the developer and manufacturer of the novel Celt ACD vascular closure device, has added a 7F-sized Celt ACD device to its range following U.S. Food and Drug Administration (FDA) approval of its premarket approval (PMA) supplement.”
“Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of the EluNIR drug-eluting stent (DES) for the treatment of patients with narrowing or blockages to their coronary arteries.”
“CorInnova Inc. recently announced it was awarded second prize in the “2017 InnoSTARS” life science competition for its EpicHeart soft-robotic heart assist device.”
“Results presented at the 2017 American Heart Association (AHA) Scientific Sessions and published in Circulation show that a new device designed to treat diastolic heart failure is safe and effective.”
“The majority of patients without health insurance who were hospitalized for heart attack, stroke or coronary artery bypass graft (CABG) surgery experienced catastrophic healthcare expenses before passage of the Affordable Care Act, according to preliminary research presented at the 2017 American Heart Association (AHA) Scientific Sessions.”
“During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presented study results comparing titan nitride oxide (TiNO) coated stents (Optimax from Hexacath) versus the Synergy bioresorbable polymer coated everolimus-eluting stent (EES) from Boston Scientific, in patients with acute coronary syndrome (ACS) patients.”
“As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings across the nation, there appears to be very little common ground upon which stakeholders agree. Yet common aspirations that are shared by most participants include better patient care, better clinical outcomes and lower costs.”
Stay Up-To-Date on jobs and industry news.
Sign up for the CathLab.com newsletter today!